Drugs which can be used in the treatment of cancer

• US 20020193371A1
• Filed: 06/20/2001
• Published: 12/19/2002
• Est. Priority Date: 06/01/2001
• Status: Abandoned Application

• Current Assignee: Molecular Engines Laboratories
• Original Assignee: Molecular Engines Laboratories
• Inventors: Tuijnder, Marius, Telerman, Adam, Amson, Robert
• Application Number:
  US09/885,031
• Publication Number:
  US 20020193371A1
• Time in Patent Office: Days
• US Class Current: 514/225.8
• CPC Class Codes: A61K 31/138 Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377
• CPC Class Codes: A61K 31/4402 only substituted in position 2, e.g. pheniramine, bisacodyl
• CPC Class Codes: A61K 31/4439 containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole nicotine A61K31/465
• CPC Class Codes: A61K 31/445 Non condensed piperidines, e.g. piperocaine
• CPC Class Codes: A61K 31/4515 having a butyrophenone group in position 1, e.g. haloperidol pipamperone A61K31/4545
• CPC Class Codes: A61K 31/496 Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• CPC Class Codes: A61K 31/4965 Non-condensed pyrazines
• CPC Class Codes: A61K 31/5415 ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia

Abstract

The present invention relates to the use of a compound inhibiting the expression of the TPT1 gene, or of the products which it controls, for producing a drug which is intended for treating cancer.

Claims

1. Use of a compound which inhibits the expression of the TPT1 gene, or of the products which it controls, for producing a drug which is intended for treating cancer.

2. Use as claimed in claim 1, characterized in that the compound inhibiting the expression of the TPT1 gene, or of the products which it controls, is an antihistamine.

3. Use as claimed in claim 2, characterized in that the antihistamine belongs to the chemical group of the piperazines and the phenothiazines.

4. Use as claimed in claim 3, characterized in that the product is selected from hydroxyzine and promethazine.

5. Use as claimed in one of claims 1 to 4, characterized in that the cancer being treated is a leukemia or a cancer of the breast.